Scientific Sessions 2024  /  New Targets and New Treatments: Advances in Lipid Therapeutics  /  Discussant: Lipoprotein a therapeutics, understanding the pipeline
Logo

American Heart Association

  161
  0

Final ID:

Discussant: Lipoprotein a therapeutics, understanding the pipeline

  • Tokgozoglu, Lale  ( HACETTEPE UNIVERSITY , Ankara , Turkey )
  • Goldberg, Anne  ( Washington Univ School of Medicine , St Louis , Missouri , United States )
    • Author Disclosures:
    Lale Tokgozoglu: DO have relevant financial relationships ; Advisor:Abbott:Active (exists now) ; Advisor:MSD:Active (exists now) ; Advisor:Novartis:Active (exists now) ; Advisor:EliLilly:Active (exists now) ; Advisor:NovoNordisk:Active (exists now) ; Speaker:Ultragenyx:Active (exists now) ; Speaker:Sanofi:Active (exists now) ; Speaker:NovoNordisk:Active (exists now) ; Speaker:Novartis:Active (exists now) ; Speaker:MSD:Active (exists now) ; Speaker:Daiichi Sankyo:Active (exists now) ; Advisor:Daiichi Sankyo:Active (exists now) ; Advisor:Sanofi:Active (exists now) ; Speaker:Amarin:Active (exists now) ; Speaker:Amgen:Active (exists now) | Anne Goldberg: DO have relevant financial relationships ; Research Funding (PI or named investigator):Amgen:Past (completed) ; Consultant:Eli Lilly:Active (exists now) ; Consultant:IONIS:Active (exists now) ; Consultant:NewAmsterdam:Active (exists now) ; Research Funding (PI or named investigator):Bio89:Active (exists now) ; Research Funding (PI or named investigator):Regeneron:Past (completed) ; Research Funding (PI or named investigator):NewAmsterdam:Active (exists now) ; Research Funding (PI or named investigator):Esperion:Active (exists now) ; Research Funding (PI or named investigator):Novartis:Active (exists now) ; Research Funding (PI or named investigator):IONIS:Active (exists now) ; Research Funding (PI or named investigator):Arrowhead:Active (exists now) ; Research Funding (PI or named investigator):Amarin:Past (completed)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

New Targets and New Treatments: Advances in Lipid Therapeutics

Monday, 11/18/2024 , 01:30PM - 02:45PM

Late-Breaking Science

More abstracts on this topic:
History and future of lipid therapeutics- a time of Renaissance

Rader Daniel, Morris Pamela

ALPACAR Phase 2 Trial of Zerlasiran: Multiple doses of a Small-Interfering RNA Targeting Lipoprotein(a) with 60 weeks Folow Up.

Nissen Steven, Dorresteijn Jannick, Fok Henry, Rider David, Romano Steve, Wolski Kathy, Rambaran Curtis, Wang Qiuqing, Nicholls Stephen, Navar Ann Marie, Ray Kausik, Schwartz Gregory, Szarek Michael, Stroes Erik, Troquay Roland

More abstracts from these authors:
How Low and How Fast Should We Go with LDL-Cholesterol?

Ray Kausik, Lloyd-jones Donald, Tokgozoglu Lale

The ODYSSEY of Lipid Lowering: Navigating the Growing Array of Therapeutics for LDL-C Reduction

Tokgozoglu Lale

You have to be authorized to contact abstract author. Please, Login
Not Available